The firm said that its newly CE-marked test for intestinal infections is suitable for use in laboratories and hospitals, and provides results in 90 minutes.
About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders.
Hallmarks of the genetic disease, which can result in life-threatening cardiac complications, include progressive weakness and loss of heart muscle.
The anonymous gift, to be made in annual installments over 10 years, will support interdisciplinary work at the campus's Genomics Institute headquarters.
Chipscreen is developing a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation.
The FDA-cleared panel includes tests for salmonella, Shiga toxin-producing Escherichia coli, Shigella, Campylobacter, and Cryptosporidium.
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
23andMe had sued Ancestry.com for, among other things, infringing a patent related to a method for determining the degree to which two people in a database are related.
Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.
UgenTec's FastFinder software platform uses artificial intelligence to enable analysis and interpretation of qPCR data, workflow automation, and genotyping.
The firm received a notice from Nasdaq on Oct. 4 saying its stock had not met the minimum $1-per-share closing price requirement for 30 consecutive business days.
The company was originally founded as a spinoff from Korean genomic services provider Macrogen to offer direct-to-consumer genomic rare disease screening tests.
The firm hopes to return fewer VUS in its test reports and to accelerate the resolution of uncertain results issued to patients in that past.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The firm will use the funding to build a high-throughput flow cytometry system that sorts cells based on high-content 3D features.
Under the agreement, Prometheus will receive an upfront payment of an undisclosed amount and could receive up to $420 million in milestone payments.
The company announced this week the expansion of a genetic testing program for US patients with inherited retinal disease that it has run with partners since 2017.
The company was founded by Washington State University scientists to offer molecular breeding and genomic services for cannabis cultivation.
The firm will validate a model system for test development, integrate key test components, and compare Spotlight to other NIPT assays.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.